lh-202512050000920148false00009201482025-12-052025-12-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
December 5, 2025
(Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
| | | | | | | | | | | | | | |
| Delaware | | 1-11353 | | 99-2588107 |
| (State or other jurisdiction of Incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | | | | | | | | | | | | | |
| 358 South Main Street | | |
| Burlington | , | North Carolina | | 27215 |
| (Address of principal executive offices) | | (Zip Code) |
(Registrant’s telephone number including area code) 336-229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol | | Name of exchange on which registered |
| Common Stock, $0.10 par value | | LH | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
| | | | | |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| On December 5, 2025, Dr. D. Gary Gilliland notified the Board of Directors (the “Board”) of Labcorp Holdings Inc. (the “Company”) of his decision to retire from the Board, effective December 31, 2025. |
| |
| Item 7.01 | Regulation FD Disclosure. |
| On December 10, 2025, the Company issued a press release announcing Dr. Gilliland’s retirement from the Board. A copy of that press release is attached to, and incorporated by reference into, this current report as Exhibit 99.1. |
| | | | | | | | |
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit | Exhibit Name |
| Exhibit 99.1 | |
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
| | | | | | | | |
|
| Date: December 10, 2025 | By: | /s/ SANDRA D. VAN DER VAART |
| | | Sandra D. van der Vaart |
| | | Executive Vice President, Chief Legal Officer and Corporate Secretary |
FOR IMMEDIATE RELEASE
Labcorp Announces Retirement of Dr. D. Gary Gilliland
from its Board of Directors
BURLINGTON, N.C., (December 10, 2025) — Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that Dr. D. Gary Gilliland will retire from its board of directors effective December 31, 2025.
“As one of the world’s leading physician-scientists and oncology executives, Dr. Gilliland’s extraordinary knowledge of all aspects of oncology and gene therapy have been invaluable to Labcorp,” said Adam Schechter, chairman and CEO. “We are grateful for his service of more than 10 years and unwavering commitment to advancing our mission to improve health and improve lives.”
“It has been an honor to serve on Labcorp’s board and help guide the evolution and growth of the organization,” said Dr. Gilliland. “I’m confident about the future as Labcorp continues to innovate, advancing important work to help transform patient care.”
Dr. Gilliland became a director of Labcorp in 2014 and has served on the Audit Committee and Quality and Compliance Committee. He has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center in Seattle since January 2020, and previously he served as the inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine and Senior Vice President of Merck Research Laboratories and Oncology Franchise Head. He also was a member of the faculty at Harvard Medical School for nearly 20 years.
“Dr. Gilliland’s leadership, strategic insight and valuable perspective have been instrumental in strengthening Labcorp,” said Dr. Garheng Kong, lead independent director and chair of the Nominating and Corporate Governance Committee. “We deeply appreciate his commitment to positioning Labcorp as a trusted global leader in innovative laboratory services, while delivering meaningful value to our stakeholders.”
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
